vTv Therapeutics Inc. Gross Margin

Gross Margin of VTVT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.


Highlights and Quick Summary

  • Gross Margin for the quarter ending September 29, 2020 was 100.0% (a 0.0% decrease compared to previous quarter)
  • Year-over-year quarterly Gross Margin decreased by 0.0%
  • Annual Gross Margin for 2019 was 100.0% (a 0.0% decrease from previous year)
  • Annual Gross Margin for 2018 was 100.0% (a 0.0% decrease from previous year)
  • Annual Gross Margin for 2017 was 100.0% (a 0.0% decrease from previous year)
  • Twelve month Gross Margin ending September 29, 2020 was 100.0% (a 0.0% decrease compared to previous quarter)
  • Twelve month trailing Gross Margin decreased by 0.0% year-over-year
Trailing Gross Margin for the last four month:
29 Sep '20 30 Mar '20 30 Dec '19 29 Sep '19
100.0% 100.0% 100.0% 100.0%
Visit stockrow.com/VTVT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of vTv Therapeutics Inc.

Most recent Gross Marginof VTVT including historical data for past 10 years.

Interactive Chart of Gross Margin of vTv Therapeutics Inc.

vTv Therapeutics Inc. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 100.0% 100.0%
2019 100.0% 100.0% 100.0% 100.0% 100.0%
2018 100.0% 100.0% 100.0% 100.0% 100.0%
2017 100.0% 100.0% 100.0% 100.0% 100.0%
2016 100.0% 100.0% 100.0% 100.0% 100.0%
2015 100.0% 100.0% 100.0% 100.0% 100.0%
2014 100.0% 100.0% 100.0%
2013 100.0%

Business Profile of vTv Therapeutics Inc.

Sector: Healthcare
Industry: Biotechnology
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.